Adicet Bio/$ACET
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adicet Bio
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Ticker
$ACET
Sector
Primary listing
Employees
102
Headquarters
Website
Adicet Bio Metrics
BasicAdvanced
$87m
-
-$13.35
-
-
Price and volume
Market cap
$87m
52-week high
$9.05
52-week low
$6.01
Average daily volume
123k
Financial strength
Current ratio
7.655
Quick ratio
7.52
Long term debt to equity
7.867
Total debt to equity
9.923
Interest coverage (TTM)
-1,928.80%
Profitability
EBITDA (TTM)
-107.756
Management effectiveness
Return on assets (TTM)
-39.44%
Return on equity (TTM)
-72.19%
Valuation
Price to book
0.57
Price to tangible book (TTM)
0.57
Price to free cash flow (TTM)
-0.741
Free cash flow yield (TTM)
-134.88%
Free cash flow per share (TTM)
-11.236
Growth
Earnings per share change (TTM)
-35.40%
3-year earnings per share growth (CAGR)
-30.78%
Adicet Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs